{
    "organizations": [],
    "uuid": "19fdc6ea5de3ca8df0ce73bd45774067d2c6050f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-indivior-asserts-new-patent-agains/brief-indivior-asserts-new-patent-against-anda-filers-idUSFWN1PY055",
    "ord_in_thread": 0,
    "title": "BRIEF-Indivior Asserts New Patent Against ANDA-Filers",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Indivior Plc:\n* INDIVIOR ASSERTS NEW PATENT AGAINST ANDA-FILERS * U.S. UNIT FILED PATENT LAWSUITS AGAINST DR. REDDY‘S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF UNITED STATES PATENT NO. 9,855,221\n* ‍PATENT RELATING TO THEIR RESPECTIVE PROPOSED GENERIC VERSIONS OF COMPANY‘S SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM PRODUCT​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T15:13:00.000+02:00",
    "crawled": "2018-02-09T16:41:31.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "indivior",
        "plc",
        "indivior",
        "asserts",
        "new",
        "patent",
        "unit",
        "filed",
        "patent",
        "lawsuit",
        "reddy",
        "actavis",
        "par",
        "alvogen",
        "teva",
        "infringement",
        "united",
        "state",
        "patent",
        "relating",
        "respective",
        "proposed",
        "generic",
        "version",
        "company",
        "buprenorphine",
        "naloxone",
        "sublingual",
        "film",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}